Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 74Carcinoma, Non-Small-Cell Lung 73Breast Neoplasms 39Lung Neoplasms 31Urinary Bladder Neoplasms 28Nasopharyngeal Carcinoma 28Ovarian Neoplasms 25Neoplasm Metastasis 21Cholangiocarcinoma 18Triple Negative Breast Neoplasms 16Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Gallbladder Neoplasms 13Biliary Tract Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Carcinoma, Transitional Cell 12Nasopharyngeal Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 9Lymphoma 7Carcinoma 7Bile Duct Neoplasms 7Lymphoma, Non-Hodgkin 6Adenocarcinoma 6Carcinoma, Hepatocellular 5Adenocarcinoma of Lung 5Neoplasms by Site 4Urothelial Cancer 3

Interventions

sintilimab 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Squamous NSCLC × Gemcitabine × Clear all
NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
357 enrolled 14 charts
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡